You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEmpagliflozin
Accession NumberDB09038
TypeSmall Molecule
GroupsApproved
DescriptionEmpagliflozin is a sodium glucose co-transporter-2 (SGLT-2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes. SGLT2 co-transporters are responsible for reabsorption of glucose from the glomerular filtrate in the kidney. The glucuretic effect resulting from SGLT2 inhibition reduces renal absorption and lowers the renal threshold for glucose, therefore resulting in increased glucose excretion. Additionally, it contributes to reduced hyperglycaemia and also assists weight loss and blood pressure reduction.
Structure
Thumb
Synonyms
(1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol
1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene
External Identifiers
  • BI 10773
  • BI-10773
  • BI10773
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
JardianceTablet10 mgOralBoehringer Ingelheim (Canada) Ltd Ltee2015-08-11Not applicableCanada
JardianceTablet25 mgOralBoehringer Ingelheim (Canada) Ltd Ltee2015-08-11Not applicableCanada
JardianceTablet, film coated10 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.2014-08-01Not applicableUs
JardianceTablet, film coated25 mg/1OralBoehringer Ingelheim Pharmaceuticals, Inc.2014-08-01Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
GlyxambiBoehringer Ingelheim Pharmaceuticals, Inc.
SynjardyBoehringer Ingelheim (Canada) Ltd Ltee
SaltsNot Available
Categories
UNIIHDC1R2M35U
CAS number864070-44-0
WeightAverage: 450.91
Monoisotopic: 450.1445309
Chemical FormulaC23H27ClO7
InChI KeyOBWASQILIWPZMG-QZMOQZSNSA-N
InChI
InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1
IUPAC Name
(2S,3R,4R,5S,6R)-2-[4-chloro-3-({4-[(3S)-oxolan-3-yloxy]phenyl}methyl)phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
SMILES
[H][C@@]1(CCOC1)OC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(O)[C@@]2([H])O)C=C1
Pharmacology
IndicationEmpagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes.
Structured Indications
PharmacodynamicsNot Available
Mechanism of actionEmpagliflozin is a sodium glucose co-transporter-2 (SGLT-2) inhibitor. SGLT2 co-transporters are responsible for reabsorption of glucose from the glomerular filtrate in the kidney. The glucuretic effect resulting from SGLT2 inhibition reduces renal absorption and lowers the renal threshold for glucose, resulting in increased glucose excretion. Additionally, it contributes to reduced hyperglycaemia, assists weight loss, and reduces blood pressure.
TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium/glucose cotransporter 2Proteinunknown
antagonist
inhibitor
HumanP31639 details
Related Articles
AbsorptionFollowing oral administration, peak plasma concentrations were reached at 1.5 hours post-dose and then declined in a biphasic manner with a rapid distribution phase and a relatively slow terminal phase. Administration following a high-fat and high-calorie meal results in a slightly lower exposure with AUC decreasing by approximately 16% and Cmax decreasing by approximately 37% compared to fasted condition.
Volume of distribution

73.8 L

Protein bindingPlasma protein binding was found to be 86.2%
Metabolism

In vitro studies suggest that empaglifozin is primarily metabolized by glucuronidation by 5'-diphospho-glucuronosyltransferases UG2B7, UGT1A3, UGT1A8, and UGT1A9. The most abundant metabolites are three glucuronide metabolites: 2-O-, 3-O-, and 6-O-glucuronide. Empagliflozin does not inhibit, inactivate, or induce CYP450 isoforms. It is a substrate for p-glycoprotein (p-gp), however in vitro studies suggest that it is unlikely to cause interactions with drugs that are p-gp substrates.

SubstrateEnzymesProduct
Empagliflozin
empagliflozin 3-O-glucuronideDetails
Route of eliminationAfter oral administration, empaglifozin was 41.2% eliminated in feces and 54.4% eliminated in urine.
Half lifeTerminal elimination half life was found to be 12.4 h based on population pharmacokinetic analysis.
Clearance

Apparent oral clearance was found to be 10.6 L/h based on population pharmacokinetic analysis.

ToxicityThe most commonly reported adverse effects for empaglifozin were urinary tract infections, female genital mycotic infections, and dyslipidemia. Because empagliflozin causes osmotic diuresis adverse reactions related to volume depletion were also reported (decreased systolic blood pressure, dehydration, hypotension, orthostatic hypotension, hypovolemia, and syncope). Impaired renal function and hypoglycemia were also reported.
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypoglycemic activities of Empagliflozin.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Empagliflozin.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideEmpagliflozin may increase the hypoglycemic activities of Acetohexamide.Withdrawn
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Empagliflozin.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Empagliflozin.Approved
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Empagliflozin.Approved, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Empagliflozin.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the hypoglycemic activities of Empagliflozin.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Amiodarone.Approved, Investigational
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Empagliflozin.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Empagliflozin.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Amphotericin B.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Empagliflozin.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Apomorphine.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Empagliflozin.Approved
AripiprazoleAripiprazole may increase the hypotensive activities of Empagliflozin.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Arotinolol.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Arsenic trioxide.Approved, Investigational
ArticaineThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Articaine.Approved
AsenapineThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Asenapine.Approved
AtazanavirThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Atazanavir.Approved, Investigational
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Empagliflozin.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Empagliflozin.Approved
BalsalazideBalsalazide may increase the hypoglycemic activities of Empagliflozin.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Empagliflozin.Experimental
BarbitalBarbital may increase the hypotensive activities of Empagliflozin.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Empagliflozin.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Empagliflozin.Approved
BenmoxinBenmoxin may increase the hypoglycemic activities of Empagliflozin.Withdrawn
BepridilThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Betamethasone.Approved, Vet Approved
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Empagliflozin.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Empagliflozin.Approved
BortezomibThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Bortezomib.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Empagliflozin.Approved
BrexpiprazoleThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Empagliflozin.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Bromocriptine.Approved, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Empagliflozin.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Bupivacaine.Approved, Investigational
BuserelinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Buserelin.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Empagliflozin.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Empagliflozin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Empagliflozin.Approved
CarbetocinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Carbetocin.Approved
CaroxazoneCaroxazone may increase the hypoglycemic activities of Empagliflozin.Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Empagliflozin.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Empagliflozin.Approved, Investigational
CeritinibThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ceritinib.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Empagliflozin.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideEmpagliflozin may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Empagliflozin.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Empagliflozin.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Cilnidipine.Approved
CinoxacinCinoxacin may increase the hypoglycemic activities of Empagliflozin.Approved, Withdrawn
CiprofloxacinCiprofloxacin may increase the hypoglycemic activities of Empagliflozin.Approved, Investigational
CitalopramCitalopram may increase the hypoglycemic activities of Empagliflozin.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Empagliflozin.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Clomipramine.Approved, Vet Approved
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Empagliflozin.Approved
ClozapineThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Conivaptan.Approved, Investigational
CorticotropinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Corticotropin.Approved, Vet Approved
Cortisone acetateThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Cortisone acetate.Approved
Cyproterone acetateThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Cyproterone acetate.Approved, Investigational
DabrafenibThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Dabrafenib.Approved
DanazolThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Danazol.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Empagliflozin.Approved
DapoxetineDapoxetine may increase the hypoglycemic activities of Empagliflozin.Investigational
DarunavirThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Darunavir.Approved
dersalazinedersalazine may increase the hypoglycemic activities of Empagliflozin.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Desflurane.Approved
DesogestrelThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Desogestrel.Approved
DesvenlafaxineDesvenlafaxine may increase the hypoglycemic activities of Empagliflozin.Approved
DexamethasoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Empagliflozin.Approved, Vet Approved
DiazoxideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Diazoxide.Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Empagliflozin.Approved
DienogestThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Dienogest.Approved
DiflunisalDiflunisal may increase the hypoglycemic activities of Empagliflozin.Approved
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Empagliflozin.Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Empagliflozin.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Dinutuximab.Approved
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Empagliflozin.Approved
DisopyramideEmpagliflozin may increase the hypoglycemic activities of Disopyramide.Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Empagliflozin.Approved
DrospirenoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Drospirenone.Approved
DuloxetineEmpagliflozin may increase the orthostatic hypotensive activities of Duloxetine.Approved
EfonidipineThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Efonidipine.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Empagliflozin.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Enalaprilat.Approved
EnoxacinEnoxacin may increase the hypoglycemic activities of Empagliflozin.Approved
EpinephrineThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Empagliflozin.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Empagliflozin.Approved
EscitalopramEscitalopram may increase the hypoglycemic activities of Empagliflozin.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Empagliflozin.Approved
EstradiolThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Estradiol.Approved, Investigational, Vet Approved
Estrone sulfateThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Estrone sulfate.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Empagliflozin.Approved
Ethinyl EstradiolThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ethinyl Estradiol.Approved
Ethynodiol diacetateThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ethynodiol diacetate.Approved
EtonogestrelThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoperidoneEtoperidone may increase the hypoglycemic activities of Empagliflozin.Approved
EverolimusThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Everolimus.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Empagliflozin.Approved, Investigational
FenoldopamThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Fenoldopam.Approved
FimasartanThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Fimasartan.Approved
FleroxacinFleroxacin may increase the hypoglycemic activities of Empagliflozin.Approved
FludrocortisoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Fludrocortisone.Approved
FlumequineFlumequine may increase the hypoglycemic activities of Empagliflozin.Withdrawn
FluoxetineFluoxetine may increase the hypoglycemic activities of Empagliflozin.Approved, Vet Approved
FluoxymesteroneFluoxymesterone may increase the hypoglycemic activities of Empagliflozin.Approved, Illicit
FluvoxamineFluvoxamine may increase the hypoglycemic activities of Empagliflozin.Approved, Investigational
FosamprenavirThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Fosamprenavir.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Empagliflozin.Approved
FurazolidoneFurazolidone may increase the hypoglycemic activities of Empagliflozin.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Empagliflozin.Approved, Vet Approved
GarenoxacinGarenoxacin may increase the hypoglycemic activities of Empagliflozin.Investigational
GatifloxacinGatifloxacin may increase the hypoglycemic activities of Empagliflozin.Approved, Investigational
GemifloxacinGemifloxacin may increase the hypoglycemic activities of Empagliflozin.Approved, Investigational
GlibornurideEmpagliflozin may increase the hypoglycemic activities of Glibornuride.Withdrawn
GliclazideEmpagliflozin may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideEmpagliflozin may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideEmpagliflozin may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneEmpagliflozin may increase the hypoglycemic activities of Gliquidone.Approved
GlisoxepideEmpagliflozin may increase the hypoglycemic activities of Glisoxepide.Approved
GlyburideEmpagliflozin may increase the hypoglycemic activities of Glyburide.Approved
GoserelinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Goserelin.Approved
GrepafloxacinGrepafloxacin may increase the hypoglycemic activities of Empagliflozin.Withdrawn
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Empagliflozin.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Halothane.Approved, Vet Approved
HexobarbitalHexobarbital may increase the hypotensive activities of Empagliflozin.Approved
HistrelinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Histrelin.Approved
HydracarbazineHydracarbazine may increase the hypoglycemic activities of Empagliflozin.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Empagliflozin.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Empagliflozin.Approved, Vet Approved
HydrocortisoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Hydroflumethiazide.Approved
Hydroxyprogesterone caproateThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
IloperidoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Imipramine.Approved
IndalpineIndalpine may increase the hypoglycemic activities of Empagliflozin.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Empagliflozin.Approved
IndinavirThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Indinavir.Approved
IndoraminThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Indoramin.Withdrawn
Insulin AspartEmpagliflozin may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirEmpagliflozin may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineEmpagliflozin may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineEmpagliflozin may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanEmpagliflozin may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproEmpagliflozin may increase the hypoglycemic activities of Insulin Lispro.Approved
Insulin PorkEmpagliflozin may increase the hypoglycemic activities of Insulin Pork.Approved
IproclozideIproclozide may increase the hypoglycemic activities of Empagliflozin.Withdrawn
IproniazidIproniazid may increase the hypoglycemic activities of Empagliflozin.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Empagliflozin.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypoglycemic activities of Empagliflozin.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Isoflurane.Approved, Vet Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Empagliflozin.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Empagliflozin.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Empagliflozin.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Empagliflozin.Approved
LabetalolThe risk or severity of adverse effects can be increased when Labetalol is combined with Empagliflozin.Approved
LacidipineThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Lacidipine.Approved
LanreotideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lanreotide.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Lercanidipine.Approved, Investigational
LeuprolideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Leuprolide.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Empagliflozin.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Levobupivacaine.Approved
LevodopaEmpagliflozin may increase the orthostatic hypotensive activities of Levodopa.Approved
LevofloxacinLevofloxacin may increase the hypoglycemic activities of Empagliflozin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the hypoglycemic activities of Empagliflozin.Approved
LevonorgestrelThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LevosimendanThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Levosimendan.Approved, Investigational
Lipoic AcidLipoic Acid may increase the hypoglycemic activities of Empagliflozin.Approved, Nutraceutical
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Empagliflozin.Approved, Investigational
LofexidineThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Lofexidine.Approved, Investigational
LomefloxacinLomefloxacin may increase the hypoglycemic activities of Empagliflozin.Approved
LopinavirThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lopinavir.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Empagliflozin.Approved
LurasidoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Lurasidone.Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Empagliflozin.Approved, Investigational
MebanazineMebanazine may increase the hypoglycemic activities of Empagliflozin.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Empagliflozin.Approved
MecaserminEmpagliflozin may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Medroxyprogesterone acetateThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Megestrol acetateThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MesalazineMesalazine may increase the hypoglycemic activities of Empagliflozin.Approved
MestranolThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Mestranol.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Empagliflozin.Approved
MethohexitalMethohexital may increase the hypotensive activities of Empagliflozin.Approved
MethotrimeprazineThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Methotrimeprazine.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Empagliflozin.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Empagliflozin.Approved
Methylene blueMethylene blue may increase the hypoglycemic activities of Empagliflozin.Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Empagliflozin.Approved
MethylprednisoloneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MethyltestosteroneMethyltestosterone may increase the hypoglycemic activities of Empagliflozin.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Empagliflozin.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Empagliflozin.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Empagliflozin.Approved, Investigational
MifepristoneEmpagliflozin may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MilnacipranMilnacipran may increase the hypoglycemic activities of Empagliflozin.Approved
MinaprineMinaprine may increase the hypoglycemic activities of Empagliflozin.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Empagliflozin.Approved
MoclobemideMoclobemide may increase the hypoglycemic activities of Empagliflozin.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Empagliflozin.Approved
MorphineThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Morphine.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the hypoglycemic activities of Empagliflozin.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Moxonidine.Approved
NabiloneThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Nabilone.Approved, Investigational
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Empagliflozin.Approved
Nalidixic AcidNalidixic Acid may increase the hypoglycemic activities of Empagliflozin.Approved
NateglinideEmpagliflozin may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 4016NCX 4016 may increase the hypoglycemic activities of Empagliflozin.Investigational
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Empagliflozin.Approved, Investigational
NefazodoneNefazodone may increase the hypoglycemic activities of Empagliflozin.Approved, Withdrawn
NelfinavirThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Nelfinavir.Approved
NemonoxacinNemonoxacin may increase the hypoglycemic activities of Empagliflozin.Investigational
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Empagliflozin.Approved, Investigational
NiacinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Niacin.Approved, Investigational, Nutraceutical
NialamideNialamide may increase the hypoglycemic activities of Empagliflozin.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Empagliflozin.Approved
NicorandilNicorandil may increase the hypotensive activities of Empagliflozin.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Empagliflozin.Approved
NilotinibThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Empagliflozin.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Empagliflozin.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may increase the hypoglycemic activities of Empagliflozin.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Empagliflozin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Empagliflozin.Approved
NorethisteroneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Norethisterone.Approved
NorfloxacinNorfloxacin may increase the hypoglycemic activities of Empagliflozin.Approved
NorgestimateThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Norgestimate.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypoglycemic activities of Empagliflozin.Withdrawn
OctreotideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Octreotide.Approved, Investigational
OfloxacinOfloxacin may increase the hypoglycemic activities of Empagliflozin.Approved
OlanzapineThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Olanzapine.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Empagliflozin.Approved, Investigational
OlsalazineOlsalazine may increase the hypoglycemic activities of Empagliflozin.Approved
OxandroloneOxandrolone may increase the hypoglycemic activities of Empagliflozin.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Oxprenolol.Approved
OxymetholoneOxymetholone may increase the hypoglycemic activities of Empagliflozin.Approved, Illicit
PaclitaxelThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Paclitaxel.Approved, Vet Approved
PaliperidoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Paliperidone.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Empagliflozin.Approved
PargylinePargyline may increase the hypoglycemic activities of Empagliflozin.Approved
ParoxetineParoxetine may increase the hypoglycemic activities of Empagliflozin.Approved, Investigational
PasireotideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Pasireotide.Approved
PazufloxacinPazufloxacin may increase the hypoglycemic activities of Empagliflozin.Investigational
PefloxacinPefloxacin may increase the hypoglycemic activities of Empagliflozin.Approved
PegvisomantPegvisomant may increase the hypoglycemic activities of Empagliflozin.Approved
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Empagliflozin.Approved, Investigational
PentamidineThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Pentamidine.Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Empagliflozin.Approved, Vet Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Empagliflozin.Approved
PhenelzinePhenelzine may increase the hypoglycemic activities of Empagliflozin.Approved
PheniprazinePheniprazine may increase the hypoglycemic activities of Empagliflozin.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Empagliflozin.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypoglycemic activities of Empagliflozin.Withdrawn
PhentolamineThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Phentolamine.Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Empagliflozin.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Pipamperone.Approved
PiperazineThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Piperazine.Approved, Vet Approved
PipotiazineThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Pipotiazine.Approved
PirlindolePirlindole may increase the hypoglycemic activities of Empagliflozin.Approved
PivhydrazinePivhydrazine may increase the hypoglycemic activities of Empagliflozin.Withdrawn
PolythiazideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Polythiazide.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Pramipexole.Approved, Investigational
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Empagliflozin.Approved
PrednisoloneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Prednisone.Approved, Vet Approved
PrimidonePrimidone may increase the hypotensive activities of Empagliflozin.Approved, Vet Approved
ProgesteroneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Progesterone.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Empagliflozin.Approved, Investigational
PrulifloxacinPrulifloxacin may increase the hypoglycemic activities of Empagliflozin.Investigational
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Empagliflozin.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Empagliflozin.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Quinethazone.Approved
QuinineEmpagliflozin may increase the hypoglycemic activities of Quinine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Empagliflozin.Approved
RasagilineRasagiline may increase the hypoglycemic activities of Empagliflozin.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Remifentanil.Approved
RepaglinideEmpagliflozin may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Empagliflozin.Approved
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Empagliflozin.Approved
RisperidoneEmpagliflozin may increase the hypotensive activities of Risperidone.Approved, Investigational
RitonavirThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ritonavir.Approved, Investigational
RopiniroleThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Ropivacaine.Approved
RosoxacinRosoxacin may increase the hypoglycemic activities of Empagliflozin.Approved
RotigotineThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Sacubitril.Approved
SafrazineSafrazine may increase the hypoglycemic activities of Empagliflozin.Withdrawn
Salicylic acidSalicylic acid may increase the hypoglycemic activities of Empagliflozin.Approved, Vet Approved
SaquinavirThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Saquinavir.Approved, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Empagliflozin.Approved, Vet Approved
SelegilineSelegiline may increase the hypoglycemic activities of Empagliflozin.Approved, Investigational, Vet Approved
SertralineSertraline may increase the hypoglycemic activities of Empagliflozin.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Sevoflurane.Approved, Vet Approved
SirolimusThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Sirolimus.Approved, Investigational
Sodium NitriteThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Sodium Nitrite.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Empagliflozin.Approved
SparfloxacinSparfloxacin may increase the hypoglycemic activities of Empagliflozin.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Empagliflozin.Approved
StanozololStanozolol may increase the hypoglycemic activities of Empagliflozin.Approved, Vet Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Streptokinase.Approved
SufentanilThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Sufentanil.Approved, Investigational
SulfadiazineEmpagliflozin may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleEmpagliflozin may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazoleEmpagliflozin may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SunitinibEmpagliflozin may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TacrolimusThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Tacrolimus.Approved, Investigational
TamsulosinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Tamsulosin.Approved, Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Empagliflozin.Approved, Investigational
TemafloxacinTemafloxacin may increase the hypoglycemic activities of Empagliflozin.Withdrawn
TemsirolimusThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Temsirolimus.Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Empagliflozin.Approved
TestosteroneTestosterone may increase the hypoglycemic activities of Empagliflozin.Approved, Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Empagliflozin.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Empagliflozin.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Thioridazine.Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Empagliflozin.Approved
TipranavirThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Empagliflozin.Approved
TolazamideEmpagliflozin may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Tolazoline.Approved, Vet Approved
TolbutamideEmpagliflozin may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Tolcapone.Approved, Withdrawn
ToloxatoneToloxatone may increase the hypoglycemic activities of Empagliflozin.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Empagliflozin.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Empagliflozin.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypoglycemic activities of Empagliflozin.Experimental
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Empagliflozin.Approved
TretinoinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Empagliflozin.Approved
TrichlormethiazideThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Trichlormethiazide.Approved, Vet Approved
TriptorelinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Triptorelin.Approved, Vet Approved
TrovafloxacinTrovafloxacin may increase the hypoglycemic activities of Empagliflozin.Approved, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Empagliflozin.Approved, Investigational
VenlafaxineVenlafaxine may increase the hypoglycemic activities of Empagliflozin.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Empagliflozin.Approved
VorinostatThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Vorinostat.Approved, Investigational
ZimelidineZimelidine may increase the hypoglycemic activities of Empagliflozin.Withdrawn
ZiprasidoneThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis Reference
  1. Wang XJ, Zhang L, Byrne D, Nummy L, Weber D, Krishnamurthy D, Yee N, Senanayake CH: Efficient synthesis of Empagliflozin, an inhibitor of SGLT-2, utilizing an AlCl3-promoted silane reduction of a beta-glycopyranoside. Org Lett. 2014 Aug 15;16(16):4090-3. doi: 10.1021/ol501755h. Epub 2014 Jul 25. Pubmed
General References
  1. Scheen AJ: Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. Clin Pharmacokinet. 2015 Jul;54(7):691-708. doi: 10.1007/s40262-015-0264-4. [PubMed:25805666 ]
  2. Gangadharan Komala M, Mather A: Empagliflozin for the treatment of Type 2 diabetes. Expert Rev Clin Pharmacol. 2014 May;7(3):271-9. doi: 10.1586/17512433.2014.908703. Epub 2014 Apr 9. [PubMed:24716752 ]
  3. Lamos EM, Younk LM, Davis SN: Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes. Expert Opin Investig Drugs. 2014 Jun;23(6):875-82. doi: 10.1517/13543784.2014.909407. Epub 2014 Apr 19. [PubMed:24746173 ]
  4. Liakos A, Karagiannis T, Athanasiadou E, Sarigianni M, Mainou M, Papatheodorou K, Bekiari E, Tsapas A: Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014 Oct;16(10):984-93. doi: 10.1111/dom.12307. Epub 2014 May 28. [PubMed:24766495 ]
  5. Haring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, Woerle HJ: Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2014 Jun;37(6):1650-9. doi: 10.2337/dc13-2105. Epub 2014 Apr 10. [PubMed:24722494 ]
  6. Neumiller JJ: Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Drugs Context. 2014 Jun 11;3:212262. doi: 10.7573/dic.212262. eCollection 2014. [PubMed:24991224 ]
  7. Bogdanffy MS, Stachlewitz RF, van Tongeren S, Knight B, Sharp DE, Ku W, Hart SE, Blanchard K: Nonclinical safety of the sodium-glucose cotransporter 2 inhibitor empagliflozin. Int J Toxicol. 2014 Nov-Dec;33(6):436-49. doi: 10.1177/1091581814551648. Epub 2014 Sep 26. [PubMed:25260362 ]
  8. Authors unspecified: Empagliflozin (Jardiance) for diabetes. Med Lett Drugs Ther. 2014 Oct 13;56(1453):99-100. [PubMed:25296258 ]
  9. Jahagirdar V, Barnett AH: Empagliflozin for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2014 Nov;15(16):2429-41. doi: 10.1517/14656566.2014.966078. [PubMed:25301180 ]
External Links
ATC CodesA10BX12A10BD19A10BD20
AHFS Codes
  • 68:20.18
PDB EntriesNot Available
FDA labelDownload (604 KB)
MSDSDownload (99 KB)
ADMET
Predicted ADMET featuresNot Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tablet, film coatedOral
TabletOral10 mg
TabletOral25 mg
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral25 mg/1
TabletOral
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6303661 No1997-04-242017-04-24Us
US6890898 No1999-02-022019-02-02Us
US7078381 No1999-02-022019-02-02Us
US7407955 No2003-08-122023-08-12Us
US7459428 No1999-02-022019-02-02Us
US7579449 No2005-11-052025-11-05Us
US7713938 No2007-04-152027-04-15Us
US8119648 No2003-08-122023-08-12Us
US8178541 No2003-08-122023-08-12Us
US8551957 No2009-10-192029-10-19Us
US8673927 No2007-05-042027-05-04Us
US8846695 No2010-06-042030-06-04Us
US8883805 No2005-11-262025-11-26Us
US9173859 No2007-05-042027-05-04Us
USUS7579449 No2005-03-152025-03-15Us
USUS7713938 No2006-04-192026-04-19Us
USWO 201416191 No2014-04-032034-04-03Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.111 mg/mLALOGPS
logP1.79ALOGPS
logP1.66ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)12.57ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area108.61 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity113.79 m3·mol-1ChemAxon
Polarizability45.24 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
ClassificationNot classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonistinhibitor
General Function:
Low-affinity glucose:sodium symporter activity
Specific Function:
Sodium-dependent glucose transporter. Has a Na(+) to glucose coupling ratio of 1:1.Efficient substrate transport in mammalian kidney is provided by the concerted action of a low affinity high capacity and a high affinity low capacity Na(+)/glucose cotransporter arranged in series along kidney proximal tubules.
Gene Name:
SLC5A2
Uniprot ID:
P31639
Molecular Weight:
72895.995 Da
References
  1. Vivian EM: Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents. Drugs Context. 2014 Dec 19;3:212264. doi: 10.7573/dic.212264. eCollection 2014. [PubMed:25598831 ]
Comments
comments powered by Disqus
Drug created on March 31, 2015 20:20 / Updated on December 07, 2016 02:40